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Abstract
Objective The objective of this study was to use a population-based dataset to evaluate the number of readmissions and
reasons for readmission in Medicare patients undergoing pancreatectomy for pancreatic cancer.
Methods We used Surveillance, Epidemiology, and End Results–Medicare linked data (1992–2003) to evaluate the initial
hospitalization, readmission rates within 30 days (early), and between 30 days and 1 year (late) after initial discharge and
reasons for readmission in patients 66 years and older undergoing pancreatectomy.
Results We identified 1,730 subjects who underwent pancreatectomy for pancreatic cancer. The in-hospital mortality was
7.5%. The overall Kaplan–Meier readmission rate was 16% at 30 days and 53% at 1 year, accounting for 15,409 additional
hospital days. Early readmissions were clearly related to operative complications in 80% of cases and unrelated diagnoses in
20% of cases. Late readmissions were related to recurrence in 48%, operative complications in 25%, and unrelated
diagnoses in 27% of cases. In a multivariate analysis, only distal pancreatic resection (P=0.02) and initial postoperative
length of stay ≥10 days (P=0.03) predicted early readmission. When compared to patients not readmitted, patients
readmitted early had worse median survival (11.8 vs.16.5 months, P=0.04), but the 5-year survival was identical (18%).
Late readmission was associated with worse median and 5-year survival (19.4 vs. 12.1 months, 12% vs. 21%, P<0.0001).
Conclusions Our study demonstrates overall 30-day and 1-year readmission rates of 16% and 53%. The majority of early
readmissions were related to postoperative complications but not related to patient and tumor characteristics. Complications
causing early readmission are a cause of early mortality and are potentially preventable. Conversely, late readmissions are
related to disease progression and are a marker of early mortality and not the cause.
Keywords Readmission.Pancreaticresection.
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Introduction
Over the last three decades, the operative mortality and
lengths of stay have decreased following pancreatic
resection,
1–6 which can be attributed to increasing region-
alization of care,
7–10 improved perioperative and critical
care,
11–13 improved prevention and management of com-
plications, implementation of critical pathways,
14,15 and
improved post-hospital inpatient and outpatient care.
Despite the improvements in mortality and lengths of stay,
the morbidity rates, usually defined as the occurrence of
any complication in the postoperative period, remain high
with reported rates in excess of 30% even at major
centers.
3,4,6,16–20 Readmission, a good measure of morbid-
ity, is rarely reported. In addition, when reported, the focus
is on readmissions within the first year.
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DOI 10.1007/s11605-009-1006-4There are three previous studies evaluating readmission
following pancreatic surgery.
16,21,22 Two studies are single-
institution studies, both of which included pancreaticoduo-
denectomy for benign and malignant disease.
16,21 Neither
study reported readmissions within 30 days of discharge.
Emick and colleagues
16 reported a 19% readmission rate in
the year after surgery in 1,643 patients undergoing
pancreaticoduodenectomy. van Geenen and colleagues
21
reported an overall 1 year readmission rate of 38% in 283
patients undergoing pancreaticoduodenectomy. Given the
single-institution nature of these studies, readmissions to
other facilities may not be identified, so the reported rates
may not reflect national readmission rates.
A population-based study using the California tumor
registry and hospital discharge data reports a 59% readmis-
sion rate in the year after pancreaticoduodenectomy in
patients with pancreatic cancer.
22 They also report de-
creased long-term survival in the group requiring readmis-
sion. The majority of readmissions were related to disease
progression. As such, they are a marker of early mortality
and not the cause. None of the above studies evaluated
readmissions using a time-to-event analysis and therefore
potentially underestimated readmission rates.
The goals of our study were to use a population-based
data set [Surveillance, Epidemiology, and End Results
(SEER)–Medicare-linked data] to evaluate the readmission
rates using time-to-event methods. We also evaluate the
reasons for readmission within 30 days of pancreatic
resection (early readmission) and between 30 days and
1 year (late readmissions). We hypothesize that early
readmissions are related to operative complications, con-
tribute to early mortality, and are potentially preventable.
Conversely, late readmissions are associated with disease
progression and are a marker, rather than a cause, of early
mortality. Therefore, it is critical to analyze 30-day
readmissions separately. We also determine the patient and
tumor factors associated with early readmission and
perform a survival analysis to determine the effect of early
and late readmission on survival.
Methods
This study was approved by the Institutional Review Board
at the University of Texas Medical Branch at Galveston. A
Data Use Agreement for the use of SEER–Medicare data
has been signed.
Data Source
We used data from the SEER–Medicare Linked Data
Project (SMLDP) for the analysis. The SEER tumor
registry is a National Cancer Institute (NCI) program,
which tracks the incidence of cancer in the USA. The
SEER database contains information on patient demograph-
ics, tumor characteristics, first course of treatment, and
survival data (obtained via linkage to the National Death
Index). From 1992–1999, SEER was comprised of 14
registries, 12 of which participated in the SEER–Medicare
linkage. After 2000, SEER had 18 registries, 16 of which
participated in the SEER–Medicare linkage.
23,24
The SMLDP includes the SEER program, the NCI, and
the Centers for Medicare and Medicaid Services). Ninety-
three percent of all SEER patients older than age 65 are
matched with Medicare enrollment files. In addition to the
variables available in SEER, claims data for hospital stays,
physician services, and hospital outpatient visits are includ-
ed. The data used in this proposal include SEER subjects
through 2002 and their Medicare claims through 2003.
Patient Cohort Selection
Using the SEER–Medicare-linked data, the following
subjects were included in the study: (1) patients with
International Classification of Diseases (ICD)-O-3 histolo-
gy codes consistent with adenocarcinoma to eliminate other
pancreatic tumor types such as neuroendocrine and acinar
cell cancers, (2) patients diagnosed between 1992 and
2002, (3) patients with a pancreatic cancer as their first
primary cancer, (4) patients enrolled in both Medicare Parts
A and B without HMO for 12 months before their cancer
diagnosis and for 1 year after their diagnosis, (5) patients
aged ≥66 (to ensure available Medicare claims data for a
full year prior to diagnosis), and (6) patients undergoing
pancreatic resection (complete resection of the primary
tumor). Pancreatic resection was identified by searching
MEDPAR inpatient claims files for ICD-9 CM codes for
total pancreatectomy, radical pancreaticoduodenectomy,
proximal pancreatectomy, distal pancreatectomy, radical
subtotal pancreatectomy, or other partial pancreatectomy
(codes shown in Table 1). Patients diagnosed at autopsy
only or patients diagnosed by death certificate only were
excluded.
Assessment of Readmissions and Diagnoses
We defined readmission as the number of patients who
were discharged from an acute care hospital and readmitted
to the hospital within (1) 30 days (early) or (2) between
30 days and 1 year (late) from the date of discharge from
the index admission for pancreatic resection. To account for
a decrease in the number of patients at risk in each time
period as a result of tumor- and operative-related deaths, a
Kaplan–Meier analysis modeling the time to readmission
was used to obtain accurate readmission rates. We cannot
directly identify patients that were transferred from one
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Procedure ICD-9 procedure codes
Total pancreatectomy 52.7
Radical pancreaticoduodenectomy 52.6
Proximal pancreatectomy 52.51
Distal pancreatectomy 52.52
Radical subtotal pancreatectomy 52.53
Other partial pancreatectomy 52.29
Upper endoscopy with or without intervention 44.13, 44.12, 44.14, 44.19, 44.12, 44.22, 44.43, 45.13, 45.16,
45.22, 45.23, 45.24, 45.25, 45.28, 45.29, 45.30, 54.59
Biliary drainage via percutaneous,
endoscopic, or operative approach
51.98, 51.87, 51.10, 51.11, 51.86, 51.85, 57.84, 51.1, 51.31, 51.51,
51.59, 51.3, 51.32, 51.42, 51.37, 51.34, 51.43, 51.49, 87.51
Diagnosis ICD-9 Diagnosis Codes
Operative complications 998, 998.0, 998.11, 998.12, 998.13, 998.3, 998.30, 998.31,
998.32, 998.4, 998.51, 998.59, 998.6, 998.83, 998.89,
998.9, 997.4, 997.5, 997.9
Metastatic disease 197, 197.0, 197.1, 197.2, 197.3, 197.4, 197.5, 197.6, 197.7,
197.8, 197.9, 198, 198.0, 198.1, 198.2, 198.3, 198.4, 198.5,
198.6, 198.7, 198.8, 198.81, 198.82, 198.89, 196.1, 196.2,
196.3, 196.4, 196.5, 196.6, 196.7, 196.8, 196.9, 199, 199.0,
199.1, 789.5
Dehydration 276, 276.0, 276.2, 276.4, 276.5, 276.50, 276.51, 276.52
Gastric outlet obstruction/delayed gastric emptying 537, 537.0, 537.3, 537.89, 537.9, 536.3, 536.8, 536.9
Venous thromboembolism/ pulmonary embolism 453.8, 444.21, 444.42, 453.1, 453.2, 453.40, 453.4, 453.42, 453.9, 415.19
Pneumonia 480.0, 480.1, 480.2, 480.3, 480.8, 480.9, 481, 481.0, 482.0, 482.1,
482.2, 482.30, 482.31, 482.32, 482.39. 482.40, 482.41, 482.42,
482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 483.0, 483.1,
483.8, 484.1, 484.3, 484.5, 484.6, 484.7, 484.8, 487.0, 486, 485
Cholangitis 576.1, 576.2, 576.8, 576.9, 572
Small bowel obstruction 560.2, 560.81, 560.89, 560.9
Gastritis/duodenitis/gastric ulcer/ duodenal ulcer 531.00, 531.01, 531.10, 531.11, 531.20, 531.21, 531.30, 531.31, 531.40,
531.41, 531.50, 531.51, 531.60, 531.61, 531.70, 531.71, 531.90,
531.91, 532.00, 532.01, 532.10, 532.11, 532.20, 532.21, 532.30, 532.31,
532.40, 532.41, 532.50, 532.51, 532.60, 532.61, 523.70, 532.71, 532.90,
532.91, 533.00, 533.01, 533.10, 533.11, 533.20, 533.21, 533.30, 533.31,
533.40, 533.41, 533.50, 533.51, 533.60, 533.61, 533.70, 533.71, 533.90,
533.91, 534.00, 534.01, 534.10, 534.11, 534.20, 534.21, 534.30, 534.31,
534.40, 534.41, 534.60, 534.61, 534.70, 534.71, 534.90, 534.91, 535.00,
535.01, 535, 535.0, 535.10, 535.11, 535.20, 535.21, 535.30, 535.31,
535.40, 535.41, 535.50, 535.51, 535.60, 535.61, 535.70, 535.71
Incisional hernia 553.20, 553.2, 553.21, 553.29, 552.2, 552.20, 552.21, 552.29, 551,
551.10, 551.00)
Pancreatic pseudocyst 577.2
Acute myocardial infarction 410, 410.0, 410.00, 410.01, 410.02, 410.10, 410.11, 410.12, 410.20,
410.21, 410.22, 410.30, 410.40, 410.41, 410.42, 410.50, 410.51,
410.52, 410.60, 410.61, 410.62, 410.70, 410.71, 410.72, 410.80,
410.82, 410.90. 410.91, 410.92
Cerebrovascular accident 435, 435.0, 435.1, 435.2, 435.3, 435.8, 235.9, 436, 437.1
Bile leak 576.4
Hip fracture 820, 820.0, 820.00, 820.01, 820.02, 820.03, 820.09, 820.10, 820.11,
820.12, 820.13, 820.19, 820.20, 820.21, 820.22, 820.30, 820.31,
820.32, 820.8, 820.9, 821.00, 821.10
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rehabilitation facility. Therefore, we excluded patients
who were readmitted on the same day they were dis-
charged, assuming these represented hospital to hospital
transfers. In many cases, patients were readmitted more
than one time over the 1-year time period.
A record was created for each readmission including the
first seven discharge diagnosis codes and the first seven
procedure codes for each hospitalization. Many patients
were readmitted more than one time. On examining the
reasons for readmissions, it was clear that reasons for
readmission were clustered among multiple readmissions in
the same patient. Over 95% of multiple readmissions in a
single patient were for the same or related diagnoses. For
this reason, we evaluated only the first readmission. For
example, if a patient was readmitted for the first time in the
early time period and again in the late time period, only the
readmission in the early time period was reexamined. We
also evaluated late readmission using a conditional repeated
events analysis, and the conclusions did not change. We
report the former.
Each readmission record was independently reviewed by
two authors. After examining the diagnosis and procedure
codes, each readmission was assigned a primary reason for
the admission. The proportion of readmissions clearly
related to postoperative complications was reported. How-
ever, these were subject to the reviewers’ interpretation.
Therefore, we also report the frequency of specific
diagnoses based on the appearance of the ICD-9 diagnosis
code anytime during admission. Each readmission record
was queried to identify the incidence of several specific
diagnoses and procedures present. The incidence of each
diagnosis or procedure in each time period was calculated
by identifying the frequency of the ICD-9 codes for each
respective diagnosis or procedure and dividing this number
by the number of first readmissions during the same time
period. These diagnoses need only be present in the
readmission diagnosis codes but did not need to be the
primary reason for readmission. As such, they do not add
up to 100%.
The ICD-9 codes used to identify specific procedures
and diagnoses are shown in Table 1. Specific procedures
evaluated included upper endoscopy with or without
intervention and biliary drainage via a percutaneous,
endoscopic, or operative approach. Specific diagnoses
evaluated included operative complications, metastatic
disease, dehydration, gastric outlet obstruction/delayed
gastric emptying, venous thromboembolism (VTE) and/or
pulmonary embolus (PE), pneumonia, cholangitis, small
bowel obstruction, gastritis/duodenitis/gastric ulcer/duode-
nal ulcer/marginal ulcer, incisional hernia, pancreatic
pseuodcyst, acute myocardial infarction, cerebrovascular
accident, bile leak, and hip fracture.
Statistical Analysis
SAS version 9.1.3 (Cary, NC) was used for all statistical
analyses. Descriptive statistics were reported for the patient
demographics, operative details, the in-hospital and 30-day
mortality, the number of patients requiring readmission
(total, within 30 days, and between 30 days and 1 year),
number of total readmissions in each time period, the
primary reason for each readmission, and the incidence of
specific diagnoses during readmissions. The diagnoses
during readmission were compared between the early and
late readmission groups using univariate statistics (chi-
square, Fisher’s exact test).
Kaplan–Meier survival curves were used to determine
readmission rates over the first year. Deaths related to
pancreatic cancer were censored at their time of death if
death occurred within the first year of discharge and prior to
any readmission. Within 30 days of discharge, there were
only 13 deaths (11 occurring without a previous readmis-
sion), so death was not a significant competing event.
Beyond 30 days, the number of deaths increased with time,
and death became a significant competing cause. We used a
Cox proportional hazards model with deaths treated as
censored values to assess patient-level predictors of readmis-
sionwithin30days.Between30daysand1year,weexcluded
patients who died or were readmitted within the first 30 days.
WethenusedtwoseparateCoxmodels:thefirsttreateddeaths
within the first year as censored and the second treated deaths
as a competing cause. The patient-level factors determining
late readmission in each model were analyzed. The assump-
tion of proportionality was tested using Schoenfeld residuals.
Significance was accepted at the P<0.05 level.
Results
Overall Cohort
Between 1992 and 2003, 1,730 subjects met the inclusion
criteria for the study. The demographic data, type of
procedure, number of in-hospital deaths, postoperative
length of stay, 30-day mortality rate (including in-hospital
deaths), and stage of disease for the overall cohort are
shown in Table 2. The mean age of the study population
was 72.6±6.4 years. Forty-eight percent of patients were
male and 82% were white. The location of the tumor
dictated the type of procedure performed. Pancreaticoduo-
denal resections were performed in 76% of patients, distal
pancreatectomy in 18% of patients, total pancreatectomy in
3% of patients, and 3% underwent pancreatectomy not
otherwise specified. The median postoperative length of
stay for all patients was 14 days (25th percentile=10 days,
75th percentile=21 days).
1966 J Gastrointest Surg (2009) 13:1963–1975Among the 1,730 patients, there were 130 in-hospital
deaths (7.5%) following surgery, leaving a total of 1,600
patients with the potential for readmission. The 30-day
mortality was 8.3% (including in-hospital mortalities); 13
patients died after the first discharge but within 30 days.
Overall Readmissions
Of the 1,600 patients with the potential for readmission,
784 patients were readmitted a total of 1,766 times within
the first year of discharge. Three hundred twenty-six
patients were readmitted once, 211 patients were readmitted
twice, 117 patients were readmitted three times, and 130
patients were readmitted four or more times. Figures 1a and
1b are Kaplan–Meier curves showing the time to readmis-
sion over the first year following discharge. Operative
deaths are censored in Fig. 1a and treated as competing
events in Fig. 1b. In addition to the survival curve, Fig. 1c
depicts the number at risk in each time period, the
cumulative readmissions at the end of each time period,
the cumulative deaths without readmission at the end of
each time period, and the Kaplan–Meier estimates for
readmission rates at the same time points. The Kaplan–
Meier curve shows a 15.5% readmission rate at 30 days and
a 52.6% readmission rate at 1 year.
The mean duration for readmission was 8.8±9.7 days
(median=6 days). Readmissions accounted for 15,409
additional hospital days in the 784 patients.
Early Readmissions
Within 30 days after discharge, 248 patients (16%) who
survived the initial hospitalization were readmitted a total
of 320 times; 190 patients were readmitted once, 46
patients were readmitted twice, and 12 patients were
readmitted three or more times. When evaluating the
individual reason for each readmission (first readmission
only), 80% were related to operative complications and
Number of patients Percent
Age at surgery 1,730 72.6±6.4 years
Gender
Male 822 48%
Female 908 52%
Race
White 1,427 82%
Black 132 8%
Hispanic 74 4%
Other 97 6%
Marital status
Married 1,044 60%
Single 250 14%
Widowed 380 22%
Unknown 56 3%
Charlson comorbidity score
0 1,108 64%
1 411 24%
2 138 8%
3 or more 73 4%
Type of procedure
Pancreaticoduodenal resection 1,309 76%
Distal pancreatectomy 311 18%
Total pancreatectomy 62 3%
Pancreatectomy, not otherwise specified 48 3%
Stage of disease
Locoregional 1,493 86%
Distant/unknown 237 14%
Postoperative length of stay 1,730 17.5±11.6 days
In-hospital mortality 130 7.5%
30-day mortality 143 8.3%
Table 2 Demographics of Over-
all Cohort (N=1,730)
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fistula, GI bleed, UTI, pneumonia, respiratory failure, and
VTE/PE. When looking for specific ICD-9 codes, the most
common diagnosis codes noted during readmission were
for operative complications (27.4%), dehydration (27.8%),
and gastric outlet obstruction/delayed gastric emptying
(8.1%). Of the patients, 19.4% had a diagnosis code for
metastatic disease, but this was often not the primary reason
for admission. A complete list of diagnoses noted during
early readmission is shown in Table 3.
Late Readmissions
There were 688 patients readmitted a total of 1,446 times
between 30 days and 1 year following the initial pancreatec-
tomy. Of the 688patients,152werealsoreadmittedwithinthe
first 30daysfollowingsurgery,leaving 536 patientsinthe late
group at risk for first readmission. Late readmission was
related to recurrence in 48%, operative complications in 25%,
and unrelated diagnoses in 27% of cases. The diagnoses
recorded during readmission in this time period differed
significantly from the reasons observed in the first 30 days
following discharge (Table 3). The most common diagnoses
during late readmissions were metastatic disease (44.0%),
dehydration (23.3%), and VTE/PE (9.1%).
Comparison of Reasons for Early and Late Readmissions
We compared the incidence of specific diagnoses during
readmission in the early and late readmission groups. These
Number (Percent) Number (Percent) Number (Percent)
560 (35.0) >= 365 days
266 (16.6) 784 (49.0) 887 (55.4) 179 − 364 days
130 (8.1) 593 (37.1) 1116 (69.8) 90 − 179 days
50 (3.1) 434 (27.1) 1213 (75.8) 60 − 89 days
29 (1.8) 358 (22.4) 1341 (83.8) 30 − 59 days
11 (0.7) 248 (15.5) 1600 (100.0) 1 − 29 days
Cumulative Deaths without 
Readmission by End of Period
Cumulative Readmissions
by End of Period
Patients at Risk at 
Beginning of Period Interval after Discharge
a
c
b
Figure 1 Kaplan–Meier curves showing the time to readmission over
the first year following initial discharge after pancreatectomy in
Medicare patients. a Kaplan–Meier curve for time to readmission with
deaths treated as censored. b Kaplan–Meier curve for time to
readmission with deaths treated as a competing event. c The table
shows the patients at risk at five different time intervals over the first
year following discharge, the cumulative readmissions, and the
cumulative deaths for five time periods, and the Kaplan–Meier
estimates of readmission rates as well as combined readmission and
death rates.
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readmission. When compared to patients in the late readmis-
sion group, patients readmitted early were more likely to be
readmitted with a diagnosis of postoperative complications,
gastric outlet obstruction/delayed gastric emptying, and
pancreatic pseudocyst. They were less likely to be readmitted
with metastatic disease, VTE/PE, and hip fractures (Table 3).
The incidence of dehydration was similar between the two
groups; however, in the late group, this diagnosis is more
related to metastatic disease and failure to thrive, whereas in
the early group, it is related postoperative complications.
Cox Proportional Hazards Model: Factors Predicting Early
Readmission
The year of surgery, age, race, sex, marital status, income,
education, Charlson comorbidity score, type of operation,
complications recorded in the billing records for the initial
hospitalization, postoperative length of stay (<10 days or
≥10 days), tumor stage, and nodal status were included in
all multivariate models. For early readmissions, only the
type of operation and the postoperative length of stay
(LOS) predicted readmission. Patients undergoing distal
pancreatectomy had a hazard ratio (HR) for readmission of
1.66 (95% CI, 1.19–2.33) when compared to those
undergoing pancreaticoduodenectomy. Patients undergoing
total pancreatectomy and pancreatectomy not otherwise
specified had the same likelihood of readmission as patients
undergoing pancreaticoduodenal resection. Patients with an
initial postoperative LOS of ≥10 days had a HR for
readmission of 1.46 (95% CI, 1.04–2.05). A recorded
diagnosis code for operative complications during initial
hospitalization (see methods) did not predict survival. The
final model is shown in Table 4.
For late readmissions, deaths due to pancreatic cancer
became a significant competing cause. Figure 1b shows a
Kaplan–Meier curve where death and readmission are both
treated as events. The rate of readmission or death within
the first year was 35% (Fig. 1c).
We ran multivariate Cox proportional hazards models,
the first with deaths as censored values at the time of death
and the second with deaths as a competing event (Table 5).
Considering deaths as censored creates informative censor-
ing, since the same factors that influence cancer deaths
likely influence late readmissions. As a result, in the first
model, treating deaths as censored, only Hispanic race and a
Charlson score of 3 or more (Table 4) predicted readmission.
In the model with death as a competing event, the presence
of distant disease at the time of surgery, positive nodal
status, a Charlson score of 3 or more, and an initial length
of stay ≥10 days predicted readmission (Table 5).
Survival Analysis
Patients readmitted within 30 days of discharge had worse
median survival (median=11.8 months; 5-year survival,
Table 3 Comparison of Reasons: Early vs. Late
Early (N=248) Late (N=536) P value
Number (%) Number (%) <0.0001
Operative complications 68 (27.4) 20 (3.7) <0.0001
Metastases 48 (19.4) 236 (44.0) <0.0001
Dehydration 69 (27.8) 125 (23.3) 0.17
Gastric outlet obstruction/delayed gastric emptying 20 (8.1) 21 (3.9) 0.02
VTE/PE 12 (4.8) 49 (9.1) 0.04
Pneumonia <11 32 (6.0) 0.10
Cholangitis 14 (5.6) 32 (6.0) 0.86
Small bowel obstruction 11 (4.4) 35 (6.5) 0.24
Gastritis/duodenitis/gastric ulcer/duodenal ulcer/marginal ulcer 15 (6.0) 34 (6.3) 0.87
Incisional hernia
a 0 (0%) <11 (<2.1%) 0.09
Pancreatic pseudocyst <11 (<4.4%) <11 (<2.1%) 0.21
Acute myocardial infarction <11 (<4.4%) <11 (<2.1%) 0.91
Cerebrovascular accident <11 (<4.4%) <11 (<2.1%) 0.93
Bile leak
b <11 (<4.4%) 0 (0%) 0.04
Hip fracture
a 0 (0%) <11 (<2.1%) 0.03
Esophagogastroduodenoscopy and related procedures 22 (8.9) 71 (13.3) 0.08
Biliary drainage (endoscopic, percutaneous, or operative) 15 (6.1) 49 (9.1) 0.14
aBoth groups <11 patients but significantly higher incidence of incisional hernias and hip fractures in the late readmission group.
bBoth groups <11 patients but significantly higher incidence of bile leaks in early readmission group.
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16.5 months; 5-year survival, 18%, p=0.04, Fig. 2, N=
248). From the curves, you can see that this difference in
mortality is early and likely attributable to postoperative
complications. Patients surviving the insult of the postop-
erative complications have similar 5-year survival rates to
those who did not suffer complications.
Readmission between 30 days and a year was associated
with worse median survival (12.1 vs. 19.4 months) and 5-
year survival (12% vs. 21%, p<0.0001, Fig. 3, N=536)
when compared to those not requiring late readmission. As a
quarter of late readmissions are related primarily to progres-
sion of disease requiring readmission, this is expected.
Multiple readmissions in the early time period were not
correlated with survival. Multiple readmissions in the late
time period were correlated with worse survival, presum-
ably from recurrent disease requiring rehospitalization,
whereas those who remained disease-free did not require
hospital admission.
Discussion
Our study demonstrates an overall readmission rate of 53%
and an early (within 30 days) readmission rate of 16% after
pancreatectomy for pancreatic cancer in Medicare patients.
Theoverallreadmissionrate,calculatedusingattime-to-event
analysis, is similar to the 59% readmission rate in a previous
population-based study
22 and higher than the reported rates
in previous single-institution studies.
16,21 The higher rates in
population-based studies more likely represent true readmis-
sion rates in the general population. Moreover, Yermilov and
colleagues
22 found that 47% of readmissions were not to the
hospital performing the primary surgery. It is likely that the
single-institution studies did not capture readmissions to
outside hospitals and may grossly underestimate readmission
rates even in their own patients. In addition, the non-time-
dependent methods used in previous studies will inflate the
denominator or number at risk in a given period, decreasing
the observed readmission rates.
Factor (reference group) HR 95% CI Type 3, P value
Length of stay ≥10 days (<10 days) 1.46 1.04–2.05 0.03
Operation (pancreaticoduodenectomy) 0.02
Distal pancreatectomy 1.66 1.19–2.33
Total pancreatectomy 1.29 0.67–2.46
Other pancreatectomy 0.76 0.31–1.88
Operative complications initial stay (yes) 0.98 0.71–1.34 0.91
Age (per year of age) 1.00 0.98–1.02 0.78
Year of surgery (per year) 1.04 1.00–1.08 0.07
Gender (male) 0.87 0.66–1.14 0.30
Race (non-Hispanic white) 0.20
Non-Hispanic black 1.03 0.62–1.70
Hispanic 0.29 0.09–0.91
Marital status (married) 0.92
Single 1.05 0.71–1.56
Widowed 1.08 0.77–1.51
Highest income quartile (1=lowest) 0.18
2 0.86 0.58–1.26
3 0.67 0.47–1.04
4 0.61 0.38–0.99
Highest education quartile (1=lowest) 0.25
2 1.28 0.85–1.93
3 1.31 0.84–2.03
4 1.67 1.01–2.75
Charlson comorbidity score (0) 0.39
1 1.06 0.77–1.44
2 1.45 0.95–2.23
3 or more 1.01 0.58–1.93
Tumor stage (distant) 0.82 0.56–1.18 0.28
Nodal status (negative) 0.98 0.74–1.30 0.98
Table 4 Cox Proportional Haz-
ards Model: Factors Associated
with Early Readmission
1970 J Gastrointest Surg (2009) 13:1963–1975As hypothesized, the length of the time period elapsed
since undergoing pancreatectomy determined the reason for
readmission. Early readmissions were more commonly
associated with postoperative complications, while late
readmission after 30 days was more likely to be due to
disease progression (metastases or recurrence).
Dehydration occurred in approximately one quarter of
patients in both the early and late groups. When evaluating
diagnosis codes concurrent with dehydration, dehydration
was more commonly related to surgical complications in
the early readmission group while dehydration in the late
group was more commonly related to chemotherapy or
recurrence of pancreatic cancer and general failure to thrive.
Likewise, the nature of postoperative complications dif-
fered between the early and late groups. Postoperative
complications requiring early readmission most commonly
included sepsis, abscess, anastomotic leak, and acute
hemorrhage, whereas late complications included small
bowel obstruction, incisional hernias, biliary strictures, and
cholangitis. A diagnosis of delayed gastric emptying or
gastric outlet obstruction was seen in 8% of early
readmissions and 4% of late readmissions. Similar to
dehydration, the reasons for the delayed gastric emptying
or gastric outlet obstruction differed between the early and
late groups. Early delayed gastric emptying following
pancreaticoduodenectomy has been reported in 10–20% of
patients immediately following pancreatic resection
3,25 and
accounts for the majority of delayed gastric emptying or
gastric outlet obstruction in the early group. In the late
group, however, this diagnosis was associated with gastric
outlet obstruction secondary to tumor recurrence.
Only the initial length of stay and the type of resection
predicted early readmission. Those who had an initial length
of stay of ten or more days were more likely to require early
Factor (reference group) Model with deaths censored Model with deaths
as competing cause
HR (95% CI)
Race (non-Hispanic white)
Non-Hispanic black 1.21 (0.88–1.67) 1.13 (0.85–1.50)
Hispanic 0.42 (0.23–0.75) 0.69 (0.46–1.01)
Charlson comorbidity score (0)
1 1.12 (0.91–1.35) 1.09 (0.91–1.29)
2 1.06 (0.74–1.50) 0.98 (0.73–1.32)
3 or more 1.78 (1.18–2.68) 1.48 (1.04–2.12)
Tumor stage (distant) 0.82 (0.62–1.08) 0.71 (0.57–0.88)
Nodal status (negative) 1.19 (0.98–1.45) 1.30 (1.11–1.53)
Length of stay ≥10 days (<10days) 1.14 (0.91–1.44) 1.23 (1.02–1.49)
Operation (pancreaticoduodenectomy)
Distal pancreatectomy 1.07 (0.83–1.38) 1.16 (0.95–1.43)
Total pancreatectomy 1.11 (0.68–1.81) 1.12 (0.75–1.66)
Other pancreatectomy 1.34 (0.83–2.17) 1.46 (0.98–2.18)
Operative complications initial stay (yes) 1.09 (0.87–1.37) 1.07 (0.88–1.28)
Age (per year of age) 0.98 (0.97–1.00) 1.00 (0.99–1.01)
Year of surgery (per year) 0.99 (0.97–1.02) 1.01 (0.98–1.03)
Gender (male) 0.84 (0.70–1.01) 0.99 (0.80–1.09)
Marital status (married)
Single 0.98 (0.75–1.28) 0.93 (0.74–1.16)
Widowed 1.08 (0.55–1.36) 1.03 (0.85–1.25)
Highest income quartile (1=lowest)
2 0.83 (0.64–1.08) 1.01 (0.80–1.26)
3 0.80 (0.60–1.07) 1.01 (0.79–1.29)
4 0.69 (0.50–0.95) 0.91 (0.70–1.20)
Highest education quartile (1=lowest)
2 1.27 (0.96–1.66) 1.10 (0.87–1.38)
3 1.19 (0.89–1.60) 1.02 (0.80–1.29)
4 1.19 (0.84–1.67) 1.00 (0.76–1.33)
Table 5 Cox Proportional Haz-
ards Model: Factors Associated
with Early Readmission
Deaths or readmissions within
30 days were excluded. The first
model treats deaths within the
first year as censored. The
second treats death as a
competing event
J Gastrointest Surg (2009) 13:1963–1975 1971readmission.Adiagnosiscodeforoperativecomplicationsdid
not predict readmission. This suggests two things: first, not all
operativecomplicationsarenotedduringinitialadmissionand
second, not all complications lead to readmission. A pro-
longed initial length of stay does not cause readmission;
rather, it is likely a marker of serious postoperative compli-
cations,themostcommondiagnosisduringearlyreadmission.
In addition, longer lengths of stay predispose patients to
developing additional iatrogenic infections, as well as VTE/PE
and atelectasis associated with prolonged immobility, which
typically occur in a hospital setting. There was no association
of age or patient comorbidities with early readmission.
This is the first study to demonstrate that patients
undergoing distal pancreatectomy have an increased risk
of readmission. This is unexpected as pancreaticoduode-
nectomy is a more complex procedure and thought to be
fraught with more complications. However, pancreatic
fistula rates have been reported to be higher following
distal pancreatectomy than pancreatic head resection.
26–28
This fact, coupled with the fact that distal pancreatectomy is
less likely to be performed at high-volume centers by
experienced surgeons,
8 likely contribute to this finding.
In the first year after initial discharge, deaths due to
pancreatic cancer became a significant competing event.
Considering deaths as censored creates informative censor-
ing, since the same factors that influence cancer deaths,
likely influence late readmissions. As a result, the multi-
variate model evaluating the factors associated with late
readmission, which treated deaths as censored, does not
demonstrate the same predictive factors as the model that
treats death as a competing event. By treating deaths a
censored, patients with advanced tumor stage (distant
disease and positive nodes) are removed from the at risk
cohort. However, these factors are related to recurrence, the
most common reason for readmission, and would likely
have led to readmission in the absence of death.
While the median survival was lower in patients
requiring early readmission compared to those who did
not, the long-term survival was identical at 18%, suggesting
that operative complications increase early deaths. Howev-
er, survivors of these complications can expect similar
survival to their counterparts who had an uncomplicated
postoperative course. Late readmission is more commonly
due to recurrence and is a marker of early mortality. As
expected, it was associated with significantly worse median
and long-term survival as shown previously.
22
This study has several limitations, mostly related to the use
ofadministrativedata.Thereportedreasonsforreadmissionin
Table 3 were based on identification of specific ICD-9
diagnosis codes both in the primary discharge diagnosis and
additional diagnoses provided for the same discharge. We
also individually reviewed each readmission record and
looked at the diagnosis and procedure codes and gave each
readmission a primary reason for the admission. The results
were similar using the two methods, in that early readmis-
sions were related to surgical complications and late
readmissions were related to recurrence; however, these
were subject to the reviewers’ interpretation.
It is often difficult to identify specific complications
commonly reported after pancreatic surgery using adminis-
trative data, including pancreatic fistula and bile leak. For
example, there are codes for postoperative complications
and anastomotic leak, but they are not specific. In addition,
the administrative data is used for billing purposes, so
diagnosis codes mandating reimbursement may be more
likely to be coded. While we were able to look at nodal
status, data were not available on margin status to evaluate
its effect on early and late readmission.
Figure 3 Kaplan–Meier actuarial survival curves showing comparing
survival in patients who did not require readmission and those who
were readmitted late (between 30 days and 1 year, N=536). Late
readmission was associated with worse median and long-term survival
(19.4 vs. 12.1 months, 21% vs. 12%, P<0.0001).
Figure 2 Kaplan–Meier actuarial survival curves showing comparing
survival in patients who did not require readmission and those who were
readmitted early (within 30 days, N=248). When compared to patients
not readmitted, patients readmitted early had worse median survival (11.8
vs.16.5 months, P=0.04), but the long-term survival was identical (18%).
1972 J Gastrointest Surg (2009) 13:1963–1975In summary, this study demonstrates the rates and the
most frequent causes of early and late readmissions and
identifies predictors of hospitalization during these time
periods after initial discharge following pancreatectomy for
pancreatic cancer. These findings reinforce the finding that
readmission rates in the general population following
pancreatectomy occur in over 50% of patients and are
underreported in single-institution studies. Additionally,
this study delineates the factors contributing to early and
late readmissions. It demonstrates that early readmission
related to complications shortens median but does not affect
long-term survival if the patient survives the operative
complication. Late readmissions are a marker of early
mortality. Death due to cancer is a competing event with
late readmission. As such, the factors influencing late
readmission are similar to those that predict early mortality.
The 15% of readmissions related to operative complications
are, therefore, potentially preventable. The reasons for early
readmissions need to be studied further to identify
individual factors and operative techniques that decrease
these preventable readmissions.
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Deepthi Martha Reddy, Presenter (University of Texas,
Galveston, TX medical student)
Discussant
Dr. Sharon Weber (Madison): First, I have to congratulate
youasamedicalstudentinpresentingthiswork.Thisisavery
timely paper and I am really happy to see it presented here at
the SSAT. As many of you know, CMS plans to use
readmission as a quality ofcareindicator inthe futurebecause
the estimated costofreadmissionshas beenestimated atabout
$17 billion. We know we have underestimated the rate of
readmission when utilizing single-institution studies because
of readmission at other hospitals. Using the SEER-Medicare
databaseisagreatwaytoobtaintheactualrateofreadmission,
so I congratulate you on this work.
I have questions surrounding two main points. First,
“how can we impact this?” and the second question
surrounding this issue—“Are these findings real?”
To address the first question, clearly, the mortality of
almost 8% in-house and 23% at 30 days is not acceptable. In
addition, the readmission rate of 16% at 30 days is also very
high, considering that the median length of stay was 14 days.
Your group has presented some of the seminal work
looking at hospital volume, and I am wondering if you did
not look at that here. Is hospital volume one area where we
may be able to impact the rate of readmission and
mortality? Were high-volume hospitals less likely to have
higher numbers of readmissions? In addition, was there any
difference in geographic patterns for readmissions?
Secondly, a recent publication by Coleman, in the New
England Journal in April 2009, examined readmissions for
Medicare patients using claims data. Of those 800,000
patients who underwent both small and larger surgical
procedures, the readmission rates at 30 days and 1 year
were almost identical to yours. Thus, this leads to the
question, “do your findings represent a real phenomenon—
that the readmission is higher after pancreatectomy, which
is clearly a more complex operation than the average
surgical procedure?” Or do these findings just imply that
the Medicare population has a higher rate of readmission
overall, perhaps because of increased age?
Closing discussant
Deepthi Martha Reddy: Thank you, Dr. Weber. We did not
include data on hospital volume. We did not do so because
some of the hospitals at which patients might go to undergo
pancreaticresectionmaynotbeincludedintheSEERregions.
As a result, they may falsely appear as low-volume hospitals.
When we evaluated hospital volume excluding hospitals
not in SEER regions, hospital volume predicted mortality,
but not readmission.
For the second question, I would like to refer to my
mentor Dr. Riall.
Closing discussant
Dr. Taylor S. Riall (Galveston, TX): We did not include
hospital volume because some of the hospitals at which
patients might undergo pancreatic resection may not be
included in the SEER regions. As a result, they may falsely
appear as low-volume hospitals. For instance, Johns Hopkins
is a high volume hospital, but it is not in a SEER region.
If you take patients who live in New Jersey, which is a
SEER region, they may travel to Baltimore to have their
surgery done at Johns Hopkins. In the database, we would be
able to identify Johns Hopkins as an individual hospital, butit
would not appear as a high volume hospital, since we would
be calculating volume based only on the number of patients
living in SEER regions who had their surgery done there.
In addition, you are looking at Medicare volume and not
total pancreatic resection volume. Therefore, there are
inherent problems with looking at hospital volume. When
we evaluated hospital volume including only hospitals in
the SEER regions, hospital volume was a predictor of
mortality and increased length of stay, but not readmission.
With regard to your question regarding Medicare
readmission rates compared to readmission rates for
pancreatectomy specifically, I think you make a good
observation. Even in the single institution studies, the
readmission rates are high. Therefore, I think this is actually
real and not simply the readmission rates for the Medicare
population. Readmission is common following pancreatec-
tomy, and we need to evaluate the reasons for readmission
and areas for improvement in a multi-institutional setting.
This can be increasingly important in this pay-for-
performance era.
Discussant
Dr. Keith D. Lillemoe (Indianapolis): Again, I would just
echo that the medical students here put us all to shame.
Great presentation.
1974 J Gastrointest Surg (2009) 13:1963–1975There is a bit of a disconnection. The 8.3%, 30-day
mortality is high. Obviously it is not a high-volume center,
tertiary center, or teaching hospital. It is a national database.
Regardless, it is still too high.
However, the 15% readmission rate is very acceptable.
Why is there such a disconnection? Is it the fact that these
people are dying before they get readmitted? I do not quite
understand your data because 15% readmission is about as
good as you are going to see from any of the best of
institutions, whereas an 8.3% mortality is unacceptably high.
Could you explain that disconnection to me? Is it
something related to the data analysis or the database that
you are using?
Closing discussant
Deepthi Martha Reddy: The early the 15% readmission
rate was related to postoperative complications. This rate is
likely lower than reported readmission rates since most
studies look at 1 year readmission rates and not 30-day
readmission rates.
Discussant
Dr. Keith Lillemoe (Indianapolis): However, do you not
anticipate that the 8.3% operative mortalities are dying of
postoperative complications? Those are not tumor progres-
sion for Whipples or pancreatic resections in 30 days.
Discussant
Dr. Charles Vollmer (Boston): I would like to shift gears
and take it from the administrative level back down to the
practice level. And the one thing that really struck me was
the fact that if you are in the hospital for greater than
10 days, you have a very high chance of being readmitted
soon thereafter.
These are cases where there is a deviation in the standard
progression of the postoperative recovery period. And I
wonder if we as surgeons can find a way to impact on that
readmission rate by figuring out what we are doing wrong,
or what is going on with the patient, in that first 10-day
period or first stay.
Therefore, in other words, what could be predictive
factors from the in-house recovery period that would say
this person should not be sent home at this point? Maybe
we are doing a disservice in trying to cut the length of stay
days down, on some of these patients when we could tidy
them up and solve the problems by keeping them in the
hospital longer. Any thoughts?
Closing discussant
Dr. Taylor S. Riall: I personally think we are seeing these
readmissions when we do not recognize postoperative
complications. When you look at the readmission rates
before and after initiation of critical pathways, you see
decreasing length of stay and the readmission rates actually
go down.
Therefore, I do not think the answer is to keep those
people there longer to prevent the complications but, as you
suggest, to identify the ones who have occult problems and
need to stay. I think the patients that get readmitted are the
occult complications that we do not recognize. For
example, we might miss a pancreatic fistula that did not
show up in the drains, so the patient appears to be “on the
pathway.” Then, we send them home, and they develop an
abscess. I am not sure we are going to be able to reduce our
readmission rates to zero, but I think it would be beneficial
for high-volume centers to pool our data and identify
factors predictive of readmission. This could potentially cut
down readmissions and cost significantly.
I think one way to do it is to continue to centralize
pancreatic resection at high volume centers. We could
incorporate these predictive factors into our pathways.
Discussant
Dr. Henry Pitt (Indianapolis, IN): We have the NSQIP
data from 2005–2007 on 2,000 pancreatectomies, and the
mortality is less than 3% in that data base.
Closing discussant
Dr. Taylor S. Riall: This is Medicare data, and I suspect the
higher observed operative mortality is expected. Increased
mortality following pancreatic surgery in elderly patients has
been well documented, so I would expect a higher rate in this
data set than NSQIP, which includes patients of all ages and
resections done for benign disease.
J Gastrointest Surg (2009) 13:1963–1975 1975